Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Effect of renal impairment on multiple‐dose pharmacokinetics of extended‐release ranolazine

Effect of renal impairment on multiple‐dose pharmacokinetics of extended‐release ranolazine Ranolazine is a novel compound under development as an antianginal agent. The multiple‐dose pharmacokinetics of extended‐release ranolazine and 3 major metabolites was investigated in healthy subjects (N = 8) and subjects with mild to severe renal impairment (N = 21). The ranolazine AUC0–12 (area under the concentration‐time curve between 0 and 12 hours after dosing) geometric mean ratio versus healthy subjects at steady state was 1.72 (90% confidence interval [CI], 1.07–2.76) in subjects with mild impairment, 1.80 (90% CI, 1.13–2.89) in those with moderate impairment, and 1.97 (90% CI, 1.23–3.16) in those with severe renal impairment. Creatinine clearance was negatively correlated with AUC0–12 and the maximum observed concentration for ranolazine and the O‐dearylated metabolite (P<.05 for all variables), as well as the N‐dealkylated metabolite (P<.001), but not for the O‐demethylated metabolite. Less than 7% of the administered dose was excreted unchanged in all groups, indicating that factors other than reduced glomerular filtration rate contributed to the increase in ranolazine concentrations in renal impairment. No serious adverse events were observed in the study. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Pharmacology & Therapeutics Wiley

Effect of renal impairment on multiple‐dose pharmacokinetics of extended‐release ranolazine

Loading next page...
 
/lp/wiley/effect-of-renal-impairment-on-multiple-dose-pharmacokinetics-of-NfkL0Ta1Fc

References (18)

Publisher
Wiley
Copyright
© 2005 American Society for Clinical Pharmacology and Therapeutics
ISSN
0009-9236
eISSN
1532-6535
DOI
10.1016/j.clpt.2005.05.004
Publisher site
See Article on Publisher Site

Abstract

Ranolazine is a novel compound under development as an antianginal agent. The multiple‐dose pharmacokinetics of extended‐release ranolazine and 3 major metabolites was investigated in healthy subjects (N = 8) and subjects with mild to severe renal impairment (N = 21). The ranolazine AUC0–12 (area under the concentration‐time curve between 0 and 12 hours after dosing) geometric mean ratio versus healthy subjects at steady state was 1.72 (90% confidence interval [CI], 1.07–2.76) in subjects with mild impairment, 1.80 (90% CI, 1.13–2.89) in those with moderate impairment, and 1.97 (90% CI, 1.23–3.16) in those with severe renal impairment. Creatinine clearance was negatively correlated with AUC0–12 and the maximum observed concentration for ranolazine and the O‐dearylated metabolite (P<.05 for all variables), as well as the N‐dealkylated metabolite (P<.001), but not for the O‐demethylated metabolite. Less than 7% of the administered dose was excreted unchanged in all groups, indicating that factors other than reduced glomerular filtration rate contributed to the increase in ranolazine concentrations in renal impairment. No serious adverse events were observed in the study.

Journal

Clinical Pharmacology & TherapeuticsWiley

Published: Sep 1, 2005

There are no references for this article.